Primary multiple BRCA associated breast cancer and ovarian cancer (clinical case)

Abstract

Introduction.The study of mutation in BRCA1/2 genes was first initiated in the USA and Europe, and later in Russia. Statistics indicate that women with the BRCA1/BRCA2 mutation have a higher risk of breast and/or ovarian cancer than the general population. According to different authors, the average cumulative risk among BRCA1 carriers is 65% (range 44–78%) for breast cancerand 39% (range 18–54%) for ovarian cancer. For mutation carriers in the BRCA2 gene, the risk for breast cancer is 45–49%, whilethe risk for RNA is 11–18%. However, in patients already diagnosed with breast cancer or ovarian cancer, the risk of a second tumorpersists throughout life and may remain high even in old age. Treatment of BRCA-associated breast cancer and/or ovarian canceris almost the same as treatment for sporadic cancer, and includes surgical, radiation, and drug anticancer therapy. However, thereare some features that need to be considered in clinical practice.Clinical case.In this article we present the clinical experience of the treatment of a 32-year-old patient with BRCA1-associated primary multiple synchronous breast cancer and metachronous uterine tube cancer. In July 2015, the patient was diagnosed withsynchronous cancer of both breast (Luminal A right breast cancer and Luminal B left breast cancer).As part of a treatment and with the patient’s consent, a bilateral adnexectomy was performed. In the histological examination ofthe operating material, the uterine tube cancer was diagnosed in situ. From 16.03.2016 to the present time the patient receivesadjuvant endocrinotherapy without signs of disease progression.Conclusion.This clinical case study presents the importance of a combined approach to the treatment and prevention of BRCAassociated cancer.